Next, we will delve into whether semaglutide can cause skin sensitivity
extended-release formulations), underscore the need for physician supervision and strict product regulation [239, 240]
Scope: Comprehensive review of ANGPTL3 inhibition as a therapeutic strategy to reduce triglyceride-rich lipoproteins and residual cardiovascular risk Therapeutic approaches discussed: Monoclonal antibodies (e.g., evinacumab) RNA-based therapies (ASOs and siRNA: vupanorsen, zodasiran, solbinsiran) Emerging gene-editing strategies (CRISPR/base editing) Key message: Targeting ANGPTL3 provides robust reductions in triglycerides, apoB-containing lipoproteins, and non-HDL cholesterol, independently of the LDL receptor Clinical relevance: Positions ANGPTL3 inhibition as a next-generation approach for managing mixed dyslipidemia and lipid-related residual risk beyond LDL-C Laura Schreier Natalia Nardelli European Atherosclerosis Society To view or add a comment, sign in Tipping the Scale in MASH: The TZD vs
Levels decrease with age, leading to thinner skin, loss of elasticity, slower healing, and more visible lines
If you want help deciding whether a personalized plan is a fit, take the free assessment quiz
Explore our treatments or speak with our experts today to find the best option for you
